260 related articles for article (PubMed ID: 22826374)
1. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study.
Lin ZZ; Shau WY; Shao YY; Yang YY; Kuo RN; Yang JC; Lai MS
Oncologist; 2012; 17(10):1294-302. PubMed ID: 22826374
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy for elderly patients with non-small-cell lung cancer.
Yamanashi K; Okumura N; Yamamoto Y; Takahashi A; Nakashima T; Matsuoka T; Kameyama K
Asian Cardiovasc Thorac Ann; 2017 Jun; 25(5):371-377. PubMed ID: 28592139
[TBL] [Abstract][Full Text] [Related]
4. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Williams CD; Gajra A; Ganti AK; Kelley MJ
Cancer; 2014 Jul; 120(13):1939-47. PubMed ID: 24668613
[TBL] [Abstract][Full Text] [Related]
5. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.
Ou SH; Zell JA; Ziogas A; Anton-Culver H
Cancer; 2007 Oct; 110(7):1532-41. PubMed ID: 17702091
[TBL] [Abstract][Full Text] [Related]
8. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
9. Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
Xie J; Zhang X; Hu S; Peng WD; Xu B; Li Y; Zhang SJ; Li Q; Li C
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2231-2239. PubMed ID: 32533405
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
12. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Zhai X; Yang L; Chen S; Zheng Q; Wang Z
Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
[TBL] [Abstract][Full Text] [Related]
13. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
Salazar MC; Rosen JE; Wang Z; Arnold BN; Thomas DC; Herbst RS; Kim AW; Detterbeck FC; Blasberg JD; Boffa DJ
JAMA Oncol; 2017 May; 3(5):610-619. PubMed ID: 28056112
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).
Kenmotsu H; Sugawara S; Watanabe Y; Saito H; Okada M; Chen-Yoshikawa TF; Ohe Y; Nishio W; Nakagawa S; Nagao H
Cancer Sci; 2022 Dec; 113(12):4327-4338. PubMed ID: 36062851
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
18. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Tsuboi M; Ohira T; Saji H; Miyajima K; Kajiwara N; Uchida O; Usuda J; Kato H
Ann Thorac Cardiovasc Surg; 2007 Apr; 13(2):73-7. PubMed ID: 17505412
[TBL] [Abstract][Full Text] [Related]
19. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
Future Oncol; 2023 Jan; 19(1):37-47. PubMed ID: 36662515
[TBL] [Abstract][Full Text] [Related]
20. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
